Navigation Links
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Date:5/31/2008

any dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of XL765 and the timing of the initiation of clinical trials for XL765. Words such as "plan," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL765 to demonstrate safety and efficacy in clinical testing, our ability to initiate and complete pivotal trials for XL765 at the referenced times; the timing and level of expenses associated with the growth of proprietary programs and other collaborations; the therapeutic and commercial value of XL765 and our other compounds; our relationship with our partners; and our ability to enter into new collaborations, continue existing co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 BreedIT Corp., (OTCQB: ... exclusive worldwide license holder and distributor of highly ... researchers, today is pleased to announce the formation ... Ltd, a leading Israeli medical Cannabis breeder. ... new breeds of medical Cannabis to meet the ...
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... ST. LOUIS, Nov. 14, 2011 Express Scripts, Inc. ... wholly owned subsidiary, Aristotle Holding, Inc., a Delaware corporation ... of a benchmark amount.  The net proceeds from the ... the cash consideration payable to stockholders of Medco Health ...
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... observations from previous clinical trials of Zerenex™ (ferric citrate) ... during the American Society of Nephrology (ASN) Kidney Week ... oral, ferric iron-based drug candidate, is currently in Phase ...
Cached Medicine Technology:Express Scripts, Inc. Launches Senior Notes Offering 2Express Scripts, Inc. Launches Senior Notes Offering 3Express Scripts, Inc. Launches Senior Notes Offering 4Express Scripts, Inc. Launches Senior Notes Offering 5Express Scripts, Inc. Launches Senior Notes Offering 6Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 2Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 3Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting 4
(Date:8/21/2014)... August 11: – Robin William’s suicide was reported ... likely due to long-term depression. , August ... Profiling investigator, appeared on the Joyce Riley Power Hour ... to help people understand why he chose not to ... proposed in terms of BioAcoustic Biology: Using vocal frequencies ...
(Date:8/21/2014)... The costs paid by consumers each year ... to insurer data. The Quotes Pros company is now helping ... its tools at http://quotespros.com . , The automatic ... with providers offering multiple coverage packages for dental related care ... public are now easier to compare using the all-in-one digital ...
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
(Date:8/21/2014)... Calcium buildup in the coronary arteries of chronic kidney ... disease risk, according to a new study in the ... ( JASN ). Researchers at the Johns Hopkins Bloomberg ... two other commonly used measures of subclinical atherosclerosis in ... kidney disease. , Approximately 50 percent of all patients ...
(Date:8/21/2014)... Texas MD Anderson Cancer Center today announced a new ... screening at a network of community breast care centers ... November, MD Anderson will become the exclusive provider of ... 10 breast care centers, located in Memorial City, The ... the network will expand to Memorial Hermann,s locations in ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Dental Insurance Now Quoted for Families Online at Insurer Portal 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:MD Anderson and Memorial Hermann to operate breast screening network across Houston area 2
... In a todays issue of The Lancet, international health ... and pharmaceutical companies to stem the epidemic of blood ... findings reveal that each year 8 million people die ... pressure-related diseases. The majority of these deaths occur in ...
... marks from ... combat surgeons, BAGHDAD, May 2 ... in Baghdad show that a new,medical device used to close a type ... civilians., A team of battle zone surgeons led by Maj. Niten ...
... May 2 CNS Response, Inc.,(OTC Bulletin Board: ... Medical Officer, CNS Response, Dr. Henry Harbin, M.D., ... Chief Medical Officer, Walden,Behavioral Care Inpatient Psychiatry and ... EEG-guided personalized medicine and,its potential for treating patients ...
... NYHealth insurance coverage and unpaid health care for full-time ... the U.S. public $45 billion a year, according to ... includes $33 billion in the cost of public coverage ... Program, and $12 billion in uncompensated care expenseswhich are ...
... AIRM ) will report financial results for the first ... the close of the market on,Thursday, May 8, 2008. ... 8, 2008 at 4:15 p.m. Eastern to discuss the ... call by dialing (888) 396-5640,(domestic) or (706) 643-0580 (international) ...
... pain to income status , , THURSDAY, May 1 (HealthDay News) ... pain much more frequently than those making more money, according ... diary in which they scored their feelings of pain on ... intervals. , People with household incomes below $30,000 a year ...
Cached Medicine News:Health News:Blood pressure killing the world's workers while banks and drug firms stand idle 2Health News:New Surgical Device Saves Lives and Limbs on Iraq's Front Lines 2Health News:New Surgical Device Saves Lives and Limbs on Iraq's Front Lines 3Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 2Health News:CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference 3Health News:$45 billion a year is spent by public on health costs for full-time workers and families 2Health News:$45 billion a year is spent by public on health costs for full-time workers and families 3Health News:$45 billion a year is spent by public on health costs for full-time workers and families 4Health News:Less Money Means More Hurting 2Health News:Less Money Means More Hurting 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: